Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Eveline B, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Jul 6;9(52):30024. doi: 10.18632/oncotarget.25776. eCollection 2018 Jul 6.

2.

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Apr 17;9(29):20323-20338. doi: 10.18632/oncotarget.24859. eCollection 2018 Apr 17. Erratum in: Oncotarget. 2018 Jul 6;9(52):30024.

3.

Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.

Tomolonis JA, Agarwal S, Shohet JM.

Cell Tissue Res. 2018 May;372(2):245-262. doi: 10.1007/s00441-017-2747-0. Epub 2017 Dec 8. Review.

4.

EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.

Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG.

Oncotarget. 2017 Oct 19;8(55):94780-94792. doi: 10.18632/oncotarget.21933. eCollection 2017 Nov 7.

5.

p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.

Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E.

Clin Cancer Res. 2017 Nov 1;23(21):6629-6639. doi: 10.1158/1078-0432.CCR-17-0668. Epub 2017 Aug 18.

PMID:
28821555
6.

CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.

Zage PE, Whittle SB, Shohet JM.

J Cell Biochem. 2017 Feb;118(2):221-231. doi: 10.1002/jcb.25656. Epub 2016 Aug 16. Review.

PMID:
27428599
7.

Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma.

Agarwal S, Ghosh R, Chen Z, Lakoma A, Gunaratne PH, Kim ES, Shohet JM.

Oncotarget. 2016 Apr 26;7(17):24018-26. doi: 10.18632/oncotarget.8116.

8.

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.

Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J.

Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208.

9.

Reactivation of p53 via MDM2 inhibition.

Kim ES, Shohet JM.

Cell Death Dis. 2015 Oct 22;6:e1936. doi: 10.1038/cddis.2015.302. No abstract available.

10.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

11.

G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response.

Kim ES, Agarwal S, Shohet JM.

Cancer Res. 2015 Sep 15;75(18):3992. doi: 10.1158/0008-5472.CAN-15-1599. Epub 2015 Sep 3. No abstract available.

12.

NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.

Shi Y, Ma IT, Patel RH, Shang X, Chen Z, Zhao Y, Cheng J, Fan Y, Rojas Y, Barbieri E, Chen Z, Yu Y, Jin J, Kim ES, Shohet JM, Vasudevan SA, Yang J.

Cell Death Dis. 2015 Aug 6;6:e1841. doi: 10.1038/cddis.2015.207.

13.

CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.

Zhang L, Agarwal S, Shohet JM, Zage PE.

Anticancer Res. 2015 Jul;35(7):3787-92.

PMID:
26124323
14.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

15.

The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.

Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, Qu C, Nathwani AC, Shohet JM, Fotsis T, Koster J, Versteeg R, Okada H, Harris AL, Davidoff AM.

J Natl Cancer Inst. 2015 Apr 29;107(6):djv080. doi: 10.1093/jnci/djv080. Print 2015 Jun.

16.

G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM.

Cancer Res. 2015 Jun 15;75(12):2566-79. doi: 10.1158/0008-5472.CAN-14-2946. Epub 2015 Apr 23.

17.

WIP1 phosphatase as a potential therapeutic target in neuroblastoma.

Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA, Kumar R.

PLoS One. 2015 Feb 6;10(2):e0115635. doi: 10.1371/journal.pone.0115635. eCollection 2015.

18.

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.

Lakoma A, Barbieri E, Agarwal S, Jackson J, Chen Z, Kim Y, McVay M, Shohet JM, Kim ES.

Cell Death Discov. 2015;1. pii: 15026. Epub 2015 Aug 24.

19.

Neuroblastoma: molecular pathogenesis and therapy.

Louis CU, Shohet JM.

Annu Rev Med. 2015;66:49-63. doi: 10.1146/annurev-med-011514-023121. Epub 2014 Oct 27. Review.

20.

In vivo Lineage-tracing Studies in a Cancer Stem Cell Population in Neuroblastoma.

Hsu DM, Shohet JM, Kim ES.

Bio Protoc. 2014 Apr 20;4(8). pii: e1104.

21.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

22.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
23.

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma.

Barbieri E, De Preter K, Capasso M, Johansson P, Man TK, Chen Z, Stowers P, Tonini GP, Speleman F, Shohet JM.

PLoS One. 2013 Nov 19;8(11):e79843. doi: 10.1371/journal.pone.0079843. eCollection 2013.

24.

Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma.

Barbieri E, De Preter K, Capasso M, Chen Z, Hsu DM, Tonini GP, Lefever S, Hicks J, Versteeg R, Pession A, Speleman F, Kim ES, Shohet JM.

Cancer Res. 2014 Feb 1;74(3):765-74. doi: 10.1158/0008-5472.CAN-13-1315. Epub 2013 Dec 12.

25.

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.

Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES, Yang J.

Cell Death Dis. 2013 Oct 17;4:e867. doi: 10.1038/cddis.2013.400.

26.

G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, Stowers PN, Courtney AN, Lakoma A, Barbieri E, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM.

Cancer Res. 2013 Jul 1;73(13):4134-46. doi: 10.1158/0008-5472.CAN-12-4056. Epub 2013 May 16.

27.

Redefining functional MYCN gene signatures in neuroblastoma.

Shohet JM.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19041-2. doi: 10.1073/pnas.1217598109. Epub 2012 Nov 8. No abstract available.

28.

A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells.

Ghosh R, Singh LC, Shohet JM, Gunaratne PH.

Biomaterials. 2013 Jan;34(3):807-16. doi: 10.1016/j.biomaterials.2012.10.023. Epub 2012 Oct 27.

PMID:
23111335
29.

Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.

Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, Chen JB, Raif A, Jankowski K, Davies NP, Bekkum MV, Chen B, Tan O, Ellis T, Norris MD, Haber M, Kim ES, Shohet JM, Trahair TN, Liu T, Wainwright BJ, Ding HF, Marshall GM.

Oncogene. 2013 Aug 1;32(31):3616-26. doi: 10.1038/onc.2012.368. Epub 2012 Aug 20.

PMID:
22907436
30.

Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery.

Patterson DM, Shohet JM, Kim ES.

Curr Protoc Pharmacol. 2011 Mar;Chapter 14:Unit 14.17. doi: 10.1002/0471141755.ph1417s52.

PMID:
21935903
31.

A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.

Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH.

Cancer Res. 2011 Jun 1;71(11):3841-51. doi: 10.1158/0008-5472.CAN-10-4391. Epub 2011 Apr 15.

32.

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.

Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.

PMID:
21484514
33.

Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma.

Russell H, Shohet JM.

Nat Rev Clin Oncol. 2011 Jan;8(1):6-8. doi: 10.1038/nrclinonc.2010.195. Epub 2010 Nov 23. No abstract available.

PMID:
21102531
34.

Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.

Shang X, Vasudevan SA, Yu Y, Ge N, Ludwig AD, Wesson CL, Wang K, Burlingame SM, Zhao YJ, Rao PH, Lu X, Russell HV, Okcu MF, Hicks MJ, Shohet JM, Donehower LA, Nuchtern JG, Yang J.

Oncogene. 2010 Sep 2;29(35):4938-46. doi: 10.1038/onc.2010.244. Epub 2010 Jun 21.

PMID:
20562916
35.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

36.

MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.

Cancer Res. 2007 Mar 15;67(6):2448-55.

37.

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.

Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM.

Mol Cancer Ther. 2006 Sep;5(9):2358-65.

38.

Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis.

Honeycutt KA, Chen Z, Koster MI, Miers M, Nuchtern J, Hicks J, Roop DR, Shohet JM.

Oncogene. 2006 Jul 6;25(29):4027-32. Epub 2006 Mar 6.

PMID:
16518415
39.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
40.

MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.

Slack A, Shohet JM.

Cell Cycle. 2005 Jul;4(7):857-60. Epub 2005 Jul 28.

PMID:
15917661
41.

Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis.

Tonelli R, Purgato S, Camerin C, Fronza R, Bologna F, Alboresi S, Franzoni M, Corradini R, Sforza S, Faccini A, Shohet JM, Marchelli R, Pession A.

Mol Cancer Ther. 2005 May;4(5):779-86.

42.

Gene profiling of high risk neuroblastoma.

Vasudevan SA, Nuchtern JG, Shohet JM.

World J Surg. 2005 Mar;29(3):317-24. Review.

PMID:
15706435
43.

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. Epub 2005 Jan 11.

44.

Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.

Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG.

Cancer Res. 2002 Feb 15;62(4):1123-8.

45.

Identification of a major binding site for complement C3 on the IgG1 heavy chain.

Shohet JM, Pemberton P, Carroll MC.

J Biol Chem. 1993 Mar 15;268(8):5866-71.

46.

Localization of the human complement component C3 binding site on the IgG heavy chain.

Shohet JM, Bergamaschini L, Davis AE, Carroll MC.

J Biol Chem. 1991 Oct 5;266(28):18520-4.

Supplemental Content

Loading ...
Support Center